The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Abstract
PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-Hodgkin’s lymphoma (NHL) patients. This phase III randomized study compares the novel radioimmunotherapy yttrium-90 (90 Y) ibritumomab tiuxetan with a control immunotherapy, rituximab, in 143 patients with relapsed or refractory low-grade, follicular, or transformed CD20+transformed NHL. PATIENTS AND METHODS: Patients received either a single intravenous (IV) dose of 90 Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73) or rituximab 375 mg/m 2 IV weekly for four doses (n = 70). The radioimmunotherapy group was pretreated with two rituximab doses (250 mg/m 2) to improve biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry. The primary end point, overall response rate (ORR), was assessed by an independent, blinded, lymphoma expert panel. RESULTS: ORR was 80% for the 90 Y ibritumomab tiuxetan group versus 56% for the rituximab group (P = .002). Complete response (CR) rates were 30% and 16% in the 90 Y ibritumomab tiuxetan and rituximab groups, respectively (P = .04). An additional 4% achieved an unconfirmed CR in each group. Kaplan-Meier estimated median duration of response was 14.2 months in the 90 Y ibritumomab tiuxetan group versus 12.1 months in the control group (P = .6), and time to progression was 11.2 versus 10.1 months (P = .173) in all patients. Durable responses of ≥ 6 months were 64% versus 47% (P = .030). Reversible myelosuppression was the primary toxicity noted with 90 Y ibritumomab tiuxetan. CONCLUSION: Radioimmunotherapy with 90 Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Self-citationMaloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Self-citationKaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 584
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Self-citationHarris, N. L. (1995) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(00)80051-4 · Cited by 527
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 359
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Self-citationPress, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., Bush, S. A., Durack, L. D., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2934 · Cited by 325
Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3270 · Cited by 286
Einfeld, D. A., Brown, J. P., Valentine, M. A., Clark, E. A., & Ledbetter, J. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02867.x · Cited by 278
Wiseman, G. A., White, C. A., Stabin, M., Dunn, W. L., Erwin, W., Dahlbom, M., Raubitschek, A., Karvelis, K., Schultheiss, T., Witzig, T. E., et al. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000276 · Cited by 234
Self-citationWiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Anthony Parker, J., Dunn, W. L., Spies, S. M., et al. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00107-x · Cited by 183
Self-citationDeNardo, G. L., DeNardo, S. J., Goldstein, D. S., Kroger, L. A., Lamborn, K. R., Levy, N. B., McGahan, J. P., Salako, Q., Shen, S., & Lewis, J. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3246 · Cited by 180
Vriesendorp, H. M., Herpst, J., Germack, M. A., Klein, J., Leichner, P. K., Loudenslager, D. M., & Order, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.6.918 · Cited by 119
Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
Vassilopoulos, G., Trobridge, G. D., Josephson, N. C., & Russell, D. W. (2001) · Blood · doi:10.1182/blood.v98.3.604 · Cited by 90
Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti- idiotype monoclonal antibodies
White, C. A., Halpern, S. E., Parker, B. A., Miller, R., Hupf, H. B., Shawler, D. L., Collins, H., & Royston, I. (1996) · Blood · doi:10.1182/blood.v87.9.3640.bloodjournal8793640 · Cited by 67
Self-citationCzuczman, M. S., Grillo-López, A. J., McLaughlin, P. J., White, C. A., Saleh, M. N., Gordon, L. I., LoBuglio, A., Rosenberg, J., Alkuzweny, B., & Maloney, D. G. (2001) · Annals of Oncology · doi:10.1023/a:1008395214584 · Cited by 67
Self-citationDeNardo, G. L., DeNardo, S. J., Kukis, D. L., OʼDonnell, R. T., Shen, S., Goldstein, D. S., Kroger, L. A., Salako, Q. A., DeNardo, D. A., Mirick, G. R., et al. (1998) · PubMed · Cited by 60
Radioimmunotherapy for lymphoma
Zelenetz, A. D. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199909000-00009 · Cited by 46
Press, O. W., Eary, J. F., Appelbaum, F. R., & Bernstein, I. D. (1995) · Cancer treatment and research · doi:10.1007/978-1-4615-2013-9_13 · Cited by 7
PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma
Gribben, J. G. (1997) · Cancer treatment and research · doi:10.1007/978-1-4615-4129-5_10 · Cited by 3
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Metadata
- Authors
- Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-López, A. J., Multani, P., & White, C. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-15
- Volume
- 20
- Issue
- 10
- Pages
- 2453-2463
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110646221
- Cited by
- 1,170
- References
- 32
- FWCI
- 76.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.